000			05425nam a22003975i 4500
988			_aSpringer_BiomedLife_2019
999			_c116759 _d116759 _x1
001			116759
003			ES-MaUEC
005			20230110040244.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190617s2019 ne | s |||| 0|eng d
020			_a9789400777422
024	7		_a10.1007/978-94-007-7742-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC847 _b2019 EB
245	0	0	_aBiomarkers in Liver Disease _cedited by Vinood B. Patel, Victor R. Preedy.
264		1	_aDordrecht, Netherlands _bSpringer International Publishing _c2019
300			_a1 recurso en línea (800 páginas) _b50 ilustraciones
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aBiomarkers in Disease: Methods Discoveries and Applications _x2542-3657
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aLiver biomarkers and their applications to nutritional interventions in animal studies -- AST-to-platelet ratio index (APRI) as marker in liver disease.-Inflammatory biomarkers in ascites -- Biomarkers for hepatocellular carcinoma in East Asia -- Liver disease and acylcarnitines as mechanistic biomarkers.-Type VI Collagen: Biological Functions and its Neo-epitope as Hepatic Fibrosis Biomarker -- Fibrinogen α-chain as a serum marker of liver disease -- Monocyte chemotactic protein-1 (cytokine, receptors,and gene polymorphisms) in hepatitis -- Biomarkers for Recurrence of Hepatocellular Carcinoma.-Graft-derived cell-free DNA as a biomarker in liver transplantation -- Serum sialic acid as a biomarker in liver disease -- CD133 and EpCAM as Biomarkers in Liver Diseases -- Traditional markers in liver disease -- Biomarkers of extracellular matrix remodeling in liver diseases -- Squamous Cell Carcinoma Antigen- Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications -- microRNA-155 and microRNA-196b in hepatitis C virus infection -- Immunological biomarkers in liver transplantation -- Phosphatidylethanol and alcohol use in liver disease patients -- Interaction of sialyltransferases, sialidases and sialic acids in liver diseases and applications to biomarker discovery -- Biomarkers to monitor graft function following liver transplantation -- YKL-40 as a biomarker of liver diseases -- Peripheral venous, portal venous, hepatic venous, arterial and intrahepatic cytokine levels as biomarkers and functional correlations -- Histological Biomarkers of Non-Alcoholic Fatty Liver Disease -- Vascular cell adhesion molecule-1 (vcam-1) expression in liver disease -- Bilirubin as a biomarker in liver disease -- Hydroxyproline as a biomarker in liver disease -- Genetic biomarkers of paracetamol-induced acute liver failure -- PNPLA3 polymorphism and Nonalcoholic Fatty Liver Disease -- Hepascore and it's application to liver disease -- Model for End-Stage Liver Disease (MELD) Score as a Biomarker -- Biomarkers in focus: Alanine Aminotransferase -- PTX3 as a biomarker of liver disease.
520	3		_aIn the past decade there has been a major sea change in the way disease is diagnosed and investigated due to the advent of high throughput technologies, such as microarrays, lab on a chip, proteomics, genomics, lipomics, metabolomics etc. These advances have enabled the discovery of new and novel markers of disease relating to autoimmune disorders, cancers, endocrine diseases, genetic disorders, sensory damage, intestinal diseases etc. In many instances these developments have gone hand in hand with the discovery of biomarkers elucidated via traditional or conventional methods, such as histopathology or clinical biochemistry. Together with microprocessor-based data analysis, advanced statistics and bioinformatics these markers have been used to identify individuals with active disease or pathology as well as those who are refractory or have distinguishing pathologies. New analytical methods that have been used to identify markers of disease and is suggested that there may be as many as 40 different platforms. Unfortunately techniques and methods have not been readily transferable to other disease states and sometimes diagnosis still relies on single analytes rather than a cohort of markers. There is thus a demand for a comprehensive and focused evidenced-based text and scientific literature that addresses these issues. Hence the formulation of Biomarkers in Disease The series covers a wide number of areas including for example, nutrition, cancer, endocrinology, cardiology, addictions, immunology, birth defects, genetics, and so on. The chapters are written by national or international experts and specialists.
650		7	_2embne _9169917 _aHígado _xEnfermedades
650		7	_2embne _aMarcadores biológicos _9162047
700	1		_aPatel, Vinood B _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _985991
700	1		_aPreedy, Victor R _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _985990
773	0		_tSpringer Nature Living Reference
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-94-007-7742-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _ek